Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Walmsley

Showing results (121-130 of 199) with videos related to

Pageof 20
Sort By:
Medicine|June 1, 2018
Viral suppression and viral rebound among young adults living with HIV in CanadaAlexis Palmer, Karyn Gabler, Beth Rachlis, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|April 10, 2026
The risk of HIV and HCV transmission in Canadians living with coinfection before, during, and after the COVID pandemic: A prospective cohort studyJim Young, Shouao Wang, Matthew Knight, et al.
The Lancet. HIV|July 22, 2017
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b studyCatherine Orrell, Debbie P Hagins, Elena Belonosova, et al.
HIV Clinical Trials|May 14, 2008
Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patientsDavid Wright, Allen Rodriguez, Eliot Godofsky, et al.
Vaccines|June 27, 2024
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent VaccinationSharon Walmsley, Majid Nabipoor, Freda Qi, et al.
The Pediatric Infectious Disease Journal|December 27, 2017
Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIVJason Brophy, Ari Bitnun, Ariane Alimenti, et al.
Current Opinion in HIV and AIDS|February 20, 2016
Which HIV patients should be screened for osteoporosis: an international perspectiveElena Alvarez, Waldo H Belloso, Mark A Boyd, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 12, 2026
Incidence and Prevalence of Human Papillomavirus Infection to Predict Outcomes from HPV-Based Cervical Cancer Screening in Women and People with a Cervix Living with HIVSofia Nicolls, Elisabeth McClymont, Marette Lee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 5, 2022
Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in CanadaGayatri Marathe, Erica E M Moodie, Marie-Josée Brouillette, et al.
Journal of Clinical Microbiology|June 8, 2006
Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping testFrançois Coutlée, Danielle Rouleau, Patrick Petignat, et al.
Pageof 20

Showing results (121-130 of 199) with videos related to

Sort By:
Pageof 20
Medicine|June 1, 2018
Viral suppression and viral rebound among young adults living with HIV in CanadaAlexis Palmer, Karyn Gabler, Beth Rachlis, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|April 10, 2026
The risk of HIV and HCV transmission in Canadians living with coinfection before, during, and after the COVID pandemic: A prospective cohort studyJim Young, Shouao Wang, Matthew Knight, et al.
The Lancet. HIV|July 22, 2017
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b studyCatherine Orrell, Debbie P Hagins, Elena Belonosova, et al.
HIV Clinical Trials|May 14, 2008
Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patientsDavid Wright, Allen Rodriguez, Eliot Godofsky, et al.
Vaccines|June 27, 2024
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent VaccinationSharon Walmsley, Majid Nabipoor, Freda Qi, et al.
The Pediatric Infectious Disease Journal|December 27, 2017
Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIVJason Brophy, Ari Bitnun, Ariane Alimenti, et al.
Current Opinion in HIV and AIDS|February 20, 2016
Which HIV patients should be screened for osteoporosis: an international perspectiveElena Alvarez, Waldo H Belloso, Mark A Boyd, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 12, 2026
Incidence and Prevalence of Human Papillomavirus Infection to Predict Outcomes from HPV-Based Cervical Cancer Screening in Women and People with a Cervix Living with HIVSofia Nicolls, Elisabeth McClymont, Marette Lee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 5, 2022
Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in CanadaGayatri Marathe, Erica E M Moodie, Marie-Josée Brouillette, et al.
Journal of Clinical Microbiology|June 8, 2006
Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping testFrançois Coutlée, Danielle Rouleau, Patrick Petignat, et al.
Pageof 20